- Home
- AIFU vs MYNZ Comparison
AIFU vs MYNZ Comparison
Compare AIFU & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFU
- MYNZ
- Stock Information
- Founded
- AIFU 1998
- MYNZ 2021
- Country
- AIFU China
- MYNZ Germany
- Employees
- AIFU N/A
- MYNZ N/A
- Industry
- AIFU
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- AIFU
- MYNZ Health Care
- Exchange
- AIFU NYSE
- MYNZ Nasdaq
- Market Cap
- AIFU 7.2M
- MYNZ 7.2M
- IPO Year
- AIFU 2007
- MYNZ 2021
- Fundamental
- Price
- AIFU $0.12
- MYNZ $3.53
- Analyst Decision
- AIFU
- MYNZ Buy
- Analyst Count
- AIFU 0
- MYNZ 2
- Target Price
- AIFU N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- AIFU 652.3K
- MYNZ 104.9K
- Earning Date
- AIFU 05-06-2025
- MYNZ 05-06-2025
- Dividend Yield
- AIFU N/A
- MYNZ N/A
- EPS Growth
- AIFU N/A
- MYNZ N/A
- EPS
- AIFU 1.15
- MYNZ N/A
- Revenue
- AIFU $247,815,758.00
- MYNZ $893,991.00
- Revenue This Year
- AIFU N/A
- MYNZ $42.95
- Revenue Next Year
- AIFU $11.81
- MYNZ N/A
- P/E Ratio
- AIFU $0.11
- MYNZ N/A
- Revenue Growth
- AIFU N/A
- MYNZ N/A
- 52 Week Low
- AIFU $0.12
- MYNZ $0.18
- 52 Week High
- AIFU $3.84
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- AIFU N/A
- MYNZ 48.27
- Support Level
- AIFU N/A
- MYNZ $3.06
- Resistance Level
- AIFU N/A
- MYNZ $3.31
- Average True Range (ATR)
- AIFU 0.00
- MYNZ 0.34
- MACD
- AIFU 0.00
- MYNZ 0.09
- Stochastic Oscillator
- AIFU 0.00
- MYNZ 93.51
About AIFU FANHUA INC SPON ADS EACH REPR 20 ORD SHS
AIFU Inc is an independent financial services provider in China. It offer end-to-end business solutions spanning compliance, technology, products, services, operations, capital flow, and professional training. It connects customers with insurance protection, retirement planning, health management, asset management, and family governance services.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.